# US 2010/0075354 A1 · Marker for identification of tissue type of epithelial ovarian cancer, and method for determination of the occurrence of epithelial ovarian cancer based on tissue type by using the marker

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0075354 A1
- Document ID: US20100075354A1
- Status: Published application
- Kind: A1
- Application number: 12/527,191
- Filed: 2008-02-15
- Published: 2010-03-25
- Earliest claimed: 2007-02-16
- Assignees: Shimadzu Corporation; Keio University
- Inventors: Taka-aki Sato; Atsuhiko Toyama; Takashi Shimada; Tetsuyoshi Sugita; Daisuke Aoki; Atsushi Suzuki; Nobuyuki Susumu; Hiroyuki Nomura
- Web page: https://patentgrep.com/patent/US20100075354A1

## CPC

- G01N 33/57545: of the ovaries
- G01N 2800/56: Staging of a disease; Further complications associated with the disease
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

It is provided a method for identification of the morbidity of epithelial ovarian cancer based on a tissue-type in view of molecular typing which is different from a conventional histopathology, and a marker for identification of a tissue-type of epithelial ovarian cancer. A method for identification of the morbidity of epithelial ovarian cancer based on a tissue-type, comprising: subjecting a sample originated from an individual of interest to a treatment for detecting at least one selected from the group consisting of biological molecules specifically showing an upregulation in expression in a specific tissue-type of epithelial ovarian cancer, and/or at least one selected from the group consisting of biological molecules specifically showing a downregulation in expression in a specific tissue-type of epithelial ovarian cancer, and identifying whether or not the significant detection of the protein is achieved, thereby identifying the tissue-type.

## Claims

### Claim 1

A method for identification of the morbidity of epithelial ovarian cancer based on a tissue-type, comprising:
subjecting a sample originated from an individual of interest to a treatment for detecting
at least one selected from the group consisting of biological molecules specifically showing an upregulation in expression in a specific tissue-type of epithelial ovarian cancer, and/or
at least one selected from the group consisting of biological molecules specifically showing a downregulation in expression in a specific tissue-type of epithelial ovarian cancer, and
identifying whether or not the significant detection of the protein is achieved, thereby identifying the tissue-type.

### Claim 2 (depends on 1)

The method for identification of the morbidity of epithelial ovarian cancer based on a tissue-type according to claim 1, wherein the group consisting of the biological molecules specifically showing an upregulation in expression in a specific tissue-type of epithelial ovarian cancer, and the group consisting of the biological molecules specifically showing a downregulation in expression in a specific tissue-type of epithelial ovarian cancer are found by profiling that includes
preparing samples originated from patients of epithelial ovarian cancer for plural tissue-types whose tissue-types are definitively diagnosed,
quantifying biological molecules expressed in the samples for each of the plural tissue-types, and
screening biological molecules whose quantified value in a specific tissue-type upregulates or downregulates by a significant variation amount relative to quantified values in other tissue-types, from biological molecules expressed in the samples.

### Claim 3 (depends on 1)

The method for identification of the morbidity of epithelial ovarian cancer based on a tissue-type according to claim 1,
wherein the group consisting of the biological molecules specifically showing an upregulation in expression in a specific tissue-type of epithelial ovarian cancer includes protein C(+) specifically showing an upregulation in expression only in Clear Cell type, protein E(+) specifically showing an upregulation in expression only in Endometrioid Carcinoma type, protein S(+) specifically showing an upregulation in expression only in Serous Adenocarcinoma type, protein M(+) specifically showing an upregulation in expression only in Mucinous Adenocarcinoma type; protein CS(+) specifically showing an upregulation in expression in Clear Cell type and in Serous Adenocarcinoma type, protein CM(+) specifically showing an upregulation in expression in Clear Cell type and in Mucinous Adenocarcinoma type, protein ES(+) specifically showing an upregulation in expression in Endometrioid Carcinoma type and in Serous Adenocarcinoma type, protein SM(+) specifically showing an upregulation in expression in Serous Adenocarcinoma type and in Mucinous Adenocarcinoma type, protein CE(+) specifically showing an upregulation in expression in Clear Cell type and in Endometrioid Carcinoma type, and protein EM(+) specifically showing an upregulation in expression in Endometrioid Carcinoma type and in Mucinous Adenocarcinoma type,
the group consisting of the biological molecules specifically showing a downregulation in expression in a specific tissue-type of epithelial ovarian cancer includes protein M(−) showing a downregulation in expression only in Mucinous Adenocarcinoma type, protein S(−) showing a downregulation in expression only in Serous Adenocarcinoma type, protein E(−) showing a downregulation in expression only in Endometrioid Carcinoma type, and protein C(−) showing a downregulation in expression only in Clear Cell type, and
detection results for a plurality of proteins arbitrarily selected from the proteins C(+), E(+), S(+), M(+), CS(+), CM(+), ES(+), SM(+), CE(+), EM(+), M(−), S(−), E(−), and C(−) are combined.

### Claim 4 (depends on 3)

The method for identification of the morbidity of epithelial ovarian cancer based on a tissue-type according to claim 3, wherein the protein C(+) specifically showing an upregulation in expression only in Clear Cell type is selected from the group consisting of
Acid ceramidase precursor,
Alpha crystallin B chain,
Annexin A1 (Annexin-1),
Annexin A4 (Annexin-4),
Carbonic anhydrase 1,
Catechol O-methyl transferase,
Cellular retinoic acid-binding protein 1,
Cystathionine gamma-lyase,
Endoplasmic reticulum protein ERp29 precursor,
Ferritin heavy chain,
Glutathione peroxidase 3 precursor,
Guanine deaminase,
Laminin subunit beta-1 precursor (Laminin B1 chain),
Laminin subunit gamma-1 precursor (Laminin B2 chain),
L-lactate dehydrogenase B chain,
Low molecular weight phosphotyrosine protein phosphatase,
Methylcrotonoyl-CoA carboxylase beta chain, mitochondrial precursor,
Nicotinamide N-methyltransferase,
Peroxiredoxin-2,
Peroxiredoxin-6,
Phosphomannomutase 2,
Phosphoserine aminotransferase,
Protein SET,
Purine nucleoside phosphorylase,
Pyridoxal kinase,
Serum amyloid P-component precursor,
SPRY domain-containing protein 4,
Superoxide dismutase [Mn], mitochondrial precursor,
Synaptic vesicle membrane protein VAT-1 homolog,
Thioredoxin domain-containing protein 12 precursor,
Transaldolase,
Triosephosphate isomerase,
Tryptophanyl-tRNA synthetase, cytoplasmic, and
Uncharacterized protein C7orf24.

### Claim 5 (depends on 3)

The method for identification of the morbidity of epithelial ovarian cancer based on a tissue-type according to claim 3, wherein the protein E(+) specifically showing an upregulation in expression only in Endometrioid Carcinoma type is selected from the group consisting of
ASRGL1 protein, and
Parvalbumin alpha.

### Claim 6 (depends on 3)

The method for identification of the morbidity of epithelial ovarian cancer based on a tissue-type according to claim 3, wherein the protein S(+) specifically showing an upregulation in expression only in Serous Adenocarcinoma type is selected from the group consisting of
Astrocytic phosphoprotein PEA-15,
c-Myc-responsive protein Rcl,
Cyclin-dependent kinase inhibitor 2A,
F-actin capping protein subunit alpha-1,
Gamma-synuclein (Breast cancer-specific gene 1 protein),
Glyoxalase domain-containing protein 4,
Ras-related protein Rab-2A,
Replication protein A 32 kDa subunit,
S100 calcium-binding protein A13,
Small ubiquitin-related modifier 2 precursor (SUMO-2), and
Ubiquinol-cytochrome c reductase complex 11 kDa protein, mitochondrial precursor.

### Claim 7 (depends on 3)

The method for identification of the morbidity of epithelial ovarian cancer based on a tissue-type according to claim 3, wherein the protein M(+) specifically showing an upregulation in expression only in Mucinous Adenocarcinoma type is selected from the group consisting of
Fatty acid-binding protein, liver,
Serpin B5 precursor (Maspin),
Thioredoxin (ATL-derived factor), and
Transgelin-2.

### Claim 8 (depends on 3)

The method for identification of the morbidity of epithelial ovarian cancer based on a tissue-type according to claim 3, wherein the protein CS(+) specifically showing an upregulation in expression only in Clear Cell type and in Serous Adenocarcinoma type is selected from the group consisting of
6-phosphogluconolactonase, and
Ubiquinol-cytochrome-c reductase complex core protein I, mitochondrial precursor.

### Claim 9 (depends on 3)

The method for identification of the morbidity of epithelial ovarian cancer based on a tissue-type according to claim 3, wherein the protein CM(+) specifically showing an upregulation in expression in Clear Cell type and in Mucinous Adenocarcinoma type is selected from the group consisting of
Carbonic anhydrase 2,
Delta(3,5)-Delta(2,4)-dienoyl-CoA isomerase,
Thiosulfate sulfurtransferase, and
Annexin A4 (Annexin-4).

### Claim 10 (depends on 3)

The method for identification of the morbidity of epithelial ovarian cancer based on a tissue-type according to claim 3, wherein the protein ES(+) specifically showing an upregulation in expression in Endometrioid Carcinoma type and in Serous Adenocarcinoma type is selected from the group consisting of
Rho GDP-dissociation inhibitor 2, and
Transgelin.

### Claim 11 (depends on 3)

The method for identification of the morbidity of epithelial ovarian cancer based on a tissue-type according to claim 3, wherein the protein SM(+) specifically showing an upregulation in expression in Serous Adenocarcinoma type and in Mucinous Adenocarcinoma type is selected from the group consisting of
Barrier-to-autointegration factor,
Cellular retinoic acid-binding protein 2,
S100 calcium-binding protein A11,
S100 calcium-binding protein A4,
S100 calcium-binding protein A6,
Selenium-binding protein 1, and
Transgelin-2.

### Claim 12 (depends on 3)

The method for identification of the morbidity of epithelial ovarian cancer based on a tissue-type according to claim 3, wherein the protein CE(+) specifically showing an upregulation in expression in Clear Cell type and in Endometrioid Carcinoma type is selected from the group consisting of
Calcyphosin, and
Fibrinogen beta chain precursor.

### Claim 13 (depends on 3)

The method for identification of the morbidity of epithelial ovarian cancer based on a tissue-type according to claim 3, wherein the protein M(−) showing a downregulation in expression only in Mucinous Adenocarcinoma type is Haloacid dehalogenase-like hydrolase domain-containing protein 2.

### Claim 14 (depends on 3)

The method for identification of the morbidity of epithelial ovarian cancer based on a tissue-type according to claim 3, wherein the protein E(−) showing a downregulation in expression only in Endometrioid Carcinoma type is selected from the group consisting of
Bis(5′-nucleosyl)-tetraphosphatase [asymmetrical],
Chloride intracellular channel protein 1, and
Monoamine-sulfating phenol sulfotransferase.

### Claim 15 (depends on 3)

The method for identification of the morbidity of epithelial ovarian cancer based on a tissue-type according to claim 3, wherein the protein C(−) showing a downregulation in expression only in Clear Cell type is selected from the group consisting of
Acyl-CoA-binding protein,
Coactosin-like protein,
SH3 domain-binding glutamic acid-rich-like protein,
Transgelin, and
Uncharacterized protein C6orf115.

### Claim 16

A marker for identification of a tissue-type of epithelial ovarian cancer, comprising, as protein C(+) specifically showing an upregulation in expression only in Clear Cell type, at least one kind of protein selected from the group consisting of
Acid ceramidase precursor,
Alpha crystallin B chain,
Annexin A1 (Annexin-1),
Annexin A4 (Annexin-4),
Carbonic anhydrase 1,
Catechol O-methyltransferase,
Cellular retinoic acid-binding protein 1,
Cystathionine gamma-lyase,
Endoplasmic reticulum protein ERp29 precursor,
Ferritin heavy chain,
Glutathione peroxidase 3 precursor,
Guanine deaminase,
Laminin subunit beta-1 precursor (Laminin B1 chain),
Laminin subunit gamma-1 precursor (Laminin B2 chain),
L-lactate dehydrogenase B chain,
Low molecular weight phosphotyrosine protein phosphatase,
Methylcrotonoyl-CoA carboxylase beta chain, mitochondrial precursor,
Nicotinamide N-methyltransferase,
Peroxiredoxin-2,
Peroxiredoxin-6,
Phosphomannomutase 2,
Phosphoserine aminotransferase,
Protein SET,
Purine nucleoside phosphorylase,
Pyridoxal kinase,
Serum amyloid P-component precursor,
SPRY domain-containing protein 4,
Superoxide dismutase [Mn], mitochondrial precursor,
Synaptic vesicle membrane protein VAT-1 homolog,
Thioredoxin domain-containing protein 12 precursor,
Transaldolase,
Triosephosphate isomerase,
Tryptophanyl-tRNA synthetase, cytoplasmic, and
Uncharacterized protein C7orf24.

### Claim 17

A marker for identification of a tissue-type of epithelial ovarian cancer, comprising, as protein E(+) specifically showing an upreagulation in expression only in Endometrioid Carcinoma type, at least one of protein selected from the group consisting of
ASRGL1 protein, and
Parvalbumin alpha.

### Claim 18

A marker for identification of a tissue-type of epithelial ovarian cancer, comprising, as protein S(+) specifically showing an upregulation in expression only in Serous Adenocarcinoma type, at least one of protein selected from the group consisting of
Astrocytic phosphoprotein PEA-15,
c-Myc-responsive protein Rcl,
Cyclin-dependent kinase inhibitor 2A,
F-actin capping protein subunit alpha-1,
Gamma-synuclein (Breast cancer-specific gene 1 protein),
Glyoxalase domain-containing protein 4,
Ras-related protein Rab-2A,
Replication protein A 32 kDa subunit,
S100 calcium-binding protein A13,
Small ubiquitin-related modifier 2 precursor (SUMO-2), and
Ubiquinol-cytochrome c reductase complex 11 kDa protein, mitochondrial precursor.

### Claim 19

A marker for identification of a tissue-type of epithelial ovarian cancer, comprising, as protein M(+) specifically showing an upregulation in expression only in Mucinous Adenocarcinoma type, at least one of protein selected from the group consisting of
Fatty acid-binding protein, liver,
Serpin B5 precursor (Maspin),
Thioredoxin (ATL-derived factor), and
Transgelin-2.

### Claim 20

A marker for identification of a tissue-type of epithelial ovarian cancer, comprising at least one of protein selected from the group consisting of:
6-phosphogluconolactonase, and
Ubiquinol-cytochrome-c reductase complex core protein I, mitochondrial precursor
as protein CS(+) specifically showing an upregulation in expression in Clear Cell type and in Serous Adenocarcinoma type;
Carbonic anhydrase 2,
Delta(3,5)-Delta(2,4)-dienoyl-CoA isomerase,
Thiosulfate sulfurtransferase, and
Annexin A4 (Annexin-4)
as protein CM(+) specifically showing an upregulation in expression in Clear Cell type and in Mucinous Adenocarcinoma type;
Rho GDP-dissociation inhibitor 2, and
Transgelin
as protein ES(+) specifically showing an upregulation in expression in Endometrioid Carcinoma type and in Serous Adenocarcinoma type;
Barrier-to-autointegration factor,
Cellular retinoic acid-binding protein 2,
S100 calcium-binding protein A11,
S100 calcium-binding protein A4,
S100 calcium-binding protein A6,
Selenium-binding protein 1, and
Transgelin-2
as protein SM(+) specifically showing an upregulation in expression in Serous Adenocarcinoma type and in Mucinous Adenocarcinoma type; and
Calcyphosin, and
Fibrinogen beta chain precursor
as protein CE(+) specifically showing an upregulation in expression in Clear Cell type and in Endometrioid Carcinoma type.

### Claim 21

A marker for identification of a tissue-type of epithelial ovarian cancer, comprising Haloacid dehalogenase-like hydrolase domain-containing protein 2 as protein M(−) showing a downregulation in expression only in Mucinous Adenocarcinoma type.

### Claim 22

A marker for identification of a tissue-type of epithelial ovarian cancer, comprising at least one protein selected from the group consisting of
Bis(5′-nucleosyl)-tetraphosphatase [asymmetrical],
Chloride intracellular channel protein 1, and
Monoamine-sulfating phenol sulfotransferase
as protein E(−) showing a downregulation in expression only in Endometrioid Carcinoma type.

### Claim 23

A marker for identification of a tissue-type of epithelial ovarian cancer, comprising at least one protein selected from the group consisting of
Acyl-CoA-binding protein,
Coactosin-like protein,
SH3 domain-binding glutamic acid-rich-like protein,
Transgelin, and
Uncharacterized protein C6orf115
as protein C(−) showing a downregulation in expression only in Clear Cell type.

### Claim 24 (depends on 16)

A kit for identification of a tissue-type of epithelial ovarian cancer, comprising at least two proteins selected from the proteins according to claim 16.

### Claim 25 (depends on 4)

The method for identification of the morbidity of epithelial ovarian cancer based on a tissue-type according to claim 4, wherein the protein S(+) specifically showing an upregulation in expression only in Serous Adenocarcinoma type is selected from the group consisting of
Astrocytic phosphoprotein PEA-15,
c-Myc-responsive protein Rcl,
Cyclin-dependent kinase inhibitor 2A,
F-actin capping protein subunit alpha-1,
Gamma-synuclein (Breast cancer-specific gene 1 protein),
Glyoxalase domain-containing protein 4,
Ras-related protein Rab-2A,
Replication protein A 32 kDa subunit,
S100 calcium-binding protein A13,
Small ubiquitin-related modifier 2 precursor (SUMO-2), and
Ubiquinol-cytochrome c reductase complex 11 kDa protein, mitochondrial precursor.

### Claim 26 (depends on 5)

The method for identification of the morbidity of epithelial ovarian cancer based on a tissue-type according to claim 5, wherein the protein S(+) specifically showing an upregulation in expression only in Serous Adenocarcinoma type is selected from the group consisting of
Astrocytic phosphoprotein PEA-15,
c-Myc-responsive protein Rcl,
Cyclin-dependent kinase inhibitor 2A,
F-actin capping protein subunit alpha-1,
Gamma-synuclein (Breast cancer-specific gene 1 protein),
Glyoxalase domain-containing protein 4,
Ras-related protein Rab-2A,
Replication protein A 32 kDa subunit,
S100 calcium-binding protein A13,
Small ubiquitin-related modifier 2 precursor (SUMO-2), and
Ubiquinol-cytochrome c reductase complex 11 kDa protein, mitochondrial precursor.

### Claim 27 (depends on 17)

A kit for identification of a tissue-type of epithelial ovarian cancer, comprising at least two proteins selected from the proteins according to claim 17.

### Claim 28 (depends on 18)

A kit for identification of a tissue-type of epithelial ovarian cancer, comprising at least two proteins selected from the proteins according to claim 18.

### Claim 29 (depends on 19)

A kit for identification of a tissue-type of epithelial ovarian cancer, comprising at least two proteins selected from the proteins according to claim 19.

### Claim 30 (depends on 20)

A kit for identification of a tissue-type of epithelial ovarian cancer, comprising at least two proteins selected from the proteins according to claim 20.

### Claim 31 (depends on 21)

A kit for identification of a tissue-type of epithelial ovarian cancer, comprising at least two proteins selected from the proteins according to claim 21.

### Claim 32 (depends on 22)

A kit for identification of a tissue-type of epithelial ovarian cancer, comprising at least two proteins selected from the proteins according to claim 22.

### Claim 33 (depends on 23)

A kit for identification of a tissue-type of epithelial ovarian cancer, comprising at least two proteins selected from the proteins according to claim 23.
